Fig. 2

NF-κB signalling pathway inhibitor (BAY 11–7082) inhibited liver fibrosis in HSCs caused by MBP-CssPLA2. a The relative mRNA levels of TNF-α in the four groups of LX-2 cells incubated with 25 μg/ml MBP, 25 μg/ml MBP-CssPLA2, 25 μg/ml FABP or 25 μg/ml MBP-CssPLA2 + 10 μΜ NF-κB inhibitor. b The relative mRNA levels of collagen III in the four groups of LX-2 cells incubated with 25 μg/ml MBP, 25 μg/ml MBP-CssPLA2, 25 μg/ml FABP or 25 μg/ml MBP-CssPLA2 + 10 μΜ NF-κB inhibitor. c The absorbance of TNF-α at 450 nm in the four groups of LX-2 cells incubated with 25 μg/ml MBP, 25 μg/ml MBP-CssPLA2, 25 μg/ml FABP or 25 μg/ml MBP-CssPLA2 + 10 μΜ NF-κB inhibitor. d The absorbance of collagen III at 450 nm in the four groups of LX-2 cells incubated with 25 μg/ml MBP, 25 μg/ml MBP-CssPLA2, 25 μg/ml FABP or 25 μg/ml MBP-CssPLA2 + 10 μΜ NF-κB inhibitor